T. Rowe Price Group Inc

Velaris Therapeutics, Paragon Labs' ninth spinout, has gone public through a reverse merger with Alaunos Therapeutics, which also included a $350 million private stock offering led by Fairmount Funds. This deal marks the eighth time Paragon has taken a startup public via reverse merger, a strategy that has gained traction in the biotech industry as an alternative to traditional IPOs. The combined company will focus on Velaris' drug programs, particularly in heart and lung diseases, alongside an obesity drug pivoted to by Alaunos.

BMO Capital analyst Brennan Hawken has maintained a Market Perform rating for T. Rowe Price Group (TROW) but lowered its price target from $120 to $110, an 8.33% decrease. Despite this, GuruFocus assesses TROW as 17.4% undervalued with a GF Value™ of $122.66 and a solid GF Score™ of 77/100, though its growth rank raises some concern. While the stock presents a potential value opportunity, recent insider selling and cautious analyst ratings suggest investors should proceed with caution.

Big bank earnings season is starting, and the T. Rowe Price Financials ETF (TFNS) will see 13 of its holdings report this week, accounting for over a third of its assets. These reports will provide crucial insights into how the financial sector is handling higher interest rates and slower hiring. Key companies like JPMorgan, Goldman Sachs, Wells Fargo, and Citigroup are among those reporting, while the fund's largest holdings, Berkshire Hathaway, Visa, and Mastercard, will not.

In the October 2026 Monthly Asset Allocation Update, Michael Walsh discusses T. Rowe Price's decision to modestly increase portfolio risk by selectively favoring US large-cap growth and emerging markets, while reducing overweight in UK equities and becoming more constructive on high-quality bonds. This strategy is driven by strong earnings growth in AI, compelling valuations in emerging markets, and the attractiveness of higher bond yields. The firm maintains a moderately pro-risk stance, prioritizing attractive fundamentals, valuations, and diversification potential.

Argus has raised its target price for Affiliated Managers Group, Inc. (AMG) to $418.00. The company, which operates through a network of affiliate investment managers, currently trades at $377.07. Investors can access a full report for more detailed analysis and insights.

T. Rowe Price Group Inc. reported its assets under management (AUM) reached $1.86 trillion as of September 30, despite experiencing net outflows of $12.2 billion in September and $28.3 billion for the quarter. The outflows included a significant defined contribution target date outflow. Equity and multi-asset holdings decreased, while alternative assets saw a slight increase, and the firm's total AUM grew by $87 billion compared to December 31, 2025.

Shares of T. Rowe Price Group Inc. (TROW) fell by 1.11% on Monday, closing at $103.99, while the broader stock market experienced mixed results. The Dow Jones Industrial Average rose, but the S&P 500 Index declined. This drop for TROW ended a three-day winning streak.

BMO Capital has lowered its price target for T. Rowe Price Group (TROW) to $110 from $120. This adjustment comes after Deutsche Bank also recently changed its price target for the company. The article notes several other analyst adjustments to T. Rowe Price's price target over the past week.

TD Cowen has raised its price target for Affiliated Managers Group (NYSE:AMG) to $523.00 from $512.00, maintaining a "buy" rating and implying a 34.61% upside. This adjustment follows AMG's strong quarterly performance, where it surpassed EPS and revenue expectations. The stock currently holds a "Moderate Buy" consensus rating from analysts, with institutional investors owning a significant 95.30% of its shares.

Invesco reported a 0.9% decline in assets under management (AUM) to $2.54 trillion in September 2026, primarily due to net long-term outflows, money-market outflows, and unfavorable market returns. Despite this monthly drop, the average total AUM for Q3 remained strong, and the company has shown encouraging longer-term AUM growth. However, sustained client outflows, market volatility, and rising expenses could challenge future growth and profitability.